C12Y 204/02008
Hypoxanthine phosphoribosyltransferase
Official title: Hypoxanthine phosphoribosyltransferase (2.4.2.8)
C12Y204/02008 (Hypoxanthine phosphoribosyltransferase) appears on 26 US grants and 51 published applications in this corpus.
Search patents in C12Y- Granted patents
- 26
- Published applications
- 51
- Assignees
- 29
- Inventors
- 90
- Latest grant
- 27 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 2 |
| 2014 | 1 | 1 |
| 2015 | 1 | 1 |
| 2016 | 0 | 0 |
| 2017 | 1 | 2 |
| 2018 | 1 | 2 |
| 2019 | 0 | 3 |
| 2020 | 1 | 0 |
| 2021 | 3 | 13 |
| 2022 | 5 | 6 |
| 2023 | 3 | 5 |
| 2024 | 2 | 7 |
| 2025 | 4 | 6 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Mesophilic argonaute systems and uses thereof27 Jan 2026US 12,534,499 B2Intima Bioscience, Inc.
- United states25 Nov 2025US 12,478,687 B2Dyne Therapeutics, Inc.
- Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping15 Jul 2025US 12,357,703 B2Dyne Therapeutics, Inc.
- Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject17 Jun 2025US 12,329,825 B1Dyne Therapeutics, Inc.
- Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of use thereof to target dystrophin and to treat Duchenne muscular dystrophy1 Apr 2025US 12,263,225 B2Dyne Therapeutics, Inc.
- Muscle targeting complexes and uses thereof for treating dystrophinopathies6 Aug 2026US 2026/0224726 A1Dyne Therapeutics, Inc.
- Muscle targeting complexes and uses thereof for treating dystrophinopathies25 Sep 2025US 2025/0297024 A1Dyne Therapeutics, Inc.
- Mannose-targeted compositions3 Jul 2025US 2025/0215042 A1Genevant Sciences GmbH
- Muscle targeting complexes and uses thereof for treating dystrophinopathies12 Jun 2025US 2025/0186605 A1Dyne Therapeutics, Inc.
- Noncovalently branched oligonucleotide compositions12 Jun 2025US 2025/0188471 A1Atalanta Therapeutics, Inc.
Most cited
By later US patents
- Muscle targeting complexes and uses thereof for treating dystrophinopathies62US 11,168,141 B2Dyne Therapeutics, Inc. · 2021
- Muscle targeting complexes and uses thereof for treating dystrophinopathies58US 11,248,056 B1Dyne Therapeutics, Inc. · 2022
- Muscle targeting complexes and uses thereof for treating dystrophinopathies56US 11,369,689 B2Dyne Therapeutics, Inc. · 2022
- Muscle targeting complexes and uses thereof for treating dystrophinopathies54US 11,497,815 B2Dyne Therapeutics, Inc. · 2022
- Muscle targeting complexes and uses thereof for treating dystrophinopathies43US 11,633,496 B2Dyne Therapeutics, Inc. · 2023